Sanofi Dupixent gets Japenese nod for chronic spontaneous urticaria Ruchika Sharma18 Feb 2024 10:00 AM ISTParis: Sanofi has announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization...
Higher-exposure to dupilumab may effect weight gain among children with eosinophilic esophagitis Niveditha Subramani2 Feb 2024 1:45 AM ISTDupilumab is a popular drug commonly marketed as Dupixent. It was first approved by the FDA in 2017 and is currently used to treat atopic dermatitis,...
Sanofi Dupixent approved by USFDA for pediatric patients aged 1 to 11 years with eosinophilic esophagitis Ruchika Sharma28 Jan 2024 2:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of...
USFDA updates Sanofi Dupixent label for atopic dermatitis Ruchika Sharma18 Jan 2024 3:00 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent (dupilumab) in atopic dermatitis,...
Dupilumab effective for refractory asthma complicated by recurring chronic eosinophilic pneumonia Dr. Shravani Dali1 Jan 2024 8:15 AM ISTDupilumab promising treatment for refractory asthma complicated by recurring chronic eosinophilic pneumonia suggests a new study published in the...
Dupilumab therapy safe against Bullous Pemphigoid finds JAMA study Jacinthlyn Sylvia22 Nov 2023 4:30 PM ISTDupilumab, a potentially novel therapy for bullous pemphigoid (BP), has shown encouraging results in a retrospective cohort study conducted by the...
Dupilumab may rapidly improve sleep parameters among patients with chronic rhinosinusitis and nasal polyps Aditi30 Oct 2023 2:30 PM ISTChronic rhinosinusitis (CRS) is a prolonged inflammation of the sinus (nasal cavity and paranasal) and is classified into CRSwNP (CRS with nasal...
Dupilumab Effective in Treating Severe Asthma with Small Airway Dysfunction Jacinthlyn Sylvia29 Oct 2023 9:45 PM ISTA real-life study uncovered the positive effects of the drug Dupilumab on severe asthma patients, marking a significant advancement in asthma...
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to Sanofi Ruchika Sharma23 Oct 2023 4:44 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Treatment of atopic dermatitis with dupilumab associated with reversible and benign Lymphoid reaction Dr. Shravani Dali20 Oct 2023 10:15 AM ISTTreatment of atopic dermatitis with dupilumab associated with reversible and benign Lymphoid reaction suggests a new study published in the JAMA...
Dupilumab Improves Sleep Quality among Chronic Rhinosinusitis patients with nasal polyps Jacinthlyn Sylvia17 Oct 2023 8:00 PM ISTChronic rhinosinusitis with nasal polyps (CRSwNP) has long been a source of discomfort for many, impacting patients' quality of life and sleep. Now, a...
Sanofi Dupixent sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for USFDA priority review Ruchika Sharma28 Sept 2023 2:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
